– USA, CA – Gemini Bioproducts, LLC, a biopharma and advanced therapy raw materials supplier, announced the appointment of Mike Stella to its Board of Directors, increasing insights into the critical supply chain needs of cell and gene therapy manufacturing – a key growth area for the company.
About Michael Stella
Mike Stella is the CEO of Ascend Advanced Therapies, a contract development and manufacturer of Adeno-Associated Virus gene therapy products headquartered in Rockville, Maryland. Mike has over 20 years of business and operations leadership experience in the manufacturing of cell and gene therapies. Before joining Ascend, he spent over 15 years at Cognate Bioservices, a cell and gene therapy CDMO, where he held executive leadership roles in operations, first as the EVP of Global Operations and for the last 7 years as the company’s COO. In his last five years at Cognate, Mike’s responsibilities increased to include the role of Board Member and CBO and COO – helping to guide the company to an exit for $875M.
“As a long-time operations executive in cell therapy development and manufacturing, I recognize the critical role that GeminiBio plays in the supply chain. The company is ideally suited to address the challenges of customers (large and small) that need quick turnaround buffer and media hydration solutions. These solutions are often critical to the process but not the science of these therapies. By leveraging GeminiBio’s solutions, companies can avoid costly investments in equipment, facilities and personnel while shortening the time to market with the life-saving treatments patients need today. I am looking forward to offering my industry and operational insights in support of GeminiBio’s continued growth and development,” said Mike Stella.
About GeminiBio
GeminiBio is a portfolio company of BelHealth Investment Partners. GeminiBio was founded in 1985 and serves the global biopharma, cell, and gene therapy industries. Its focus is on helping customers (from basic research to commercial production) accelerate the development of life-enhancing biotherapeutics by streamlining and improving their cell culture and process liquid manufacturing workflows.
The company provides critical raw materials used in cell therapy, gene therapy, and biotherapeutics manufacturing – including serum, customized media and buffers solutions, and process liquids.
Located in West Sacramento, California, GeminiBio has 57,000 square feet of cGMP manufacturing space, segregated between animal origin-free and animal component manufacturing. GeminiBio is an ISO 13485:2016 certified, FDA-registered Class 1 Medical Device Manufacturer, aligned with 21 CFR Part 820.
For more information: https://www.geminibio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.